caa a22 4500 397496737 CHVBK 20180308164523.0 cr unu---uuuuu 161202e199504 xx s 000 0 eng 10.1016/S1010-7940(05)80142-3 doi (NATIONALLICENCE)oxford-10.1016/S1010-7940(05)80142-3 Long-term follow-up of different models of mechanical and biological mitral prostheses [Elektronische Daten] Three hundred eighty-five valve prostheses were implanted between 1974and 1981 in patients with isolated mitral disease: 157 caged-ball valves(156 Starr-Edwards; 1 Smeloff-Cutter) (group A), 107 tilting- disc valves(44 Bjork-Shiley, 49 Sorin, 14 Lillehei-Kaster) (group B), 121 porcinebioprostheses (45 Carpentier-Edwards, 66 Liotta, 10 Hancock) (group C).Perioperative mortality was 9.5% in group A, 11.2% in group B and 6.6% ingroup C. The follow-up was 86% complete. Actuarial freedom fromcomplications was calculated as follows (linearised rates in brackets) ingroups A, B and C, respectively: survival: 47.01% +/- 0.11 (3% patient/yr),53.37% +/- 0.08 (1.8% patient/yr), 61.24% +/- 0.05 (2.2% patient/yr);thromboembolism: 67.94% +/- 0.09 (1.18% patient/yr); 73.07% +/- 0.06 (1%patient/yr); 97.43% +/- 0.02 (0.02% patient/yr); anticoagulation-relatedhemorrhage: 84.10% +/- 0.13 (0.18% patient/yr), 97.21% +/- 0.01 (0.12%patient/yr), 100%; prosthetic valve endocarditis: 100% in groups A and B,95.76% +/- 0.02 (0.18% patient/yr) in group C; valve-related mortality:87.52% +/- 0.03 (0.75% patient/yr), 87.96% +/- 0.03 (0.56% patient/yr),82.53% +/- 0.04 (0.93% patient/yr); valve failure: 81.22% +/- 0.07 (0.56%patient/yr), 63.36% +/- 0.1 (1.06% patient/yr), 14.31% +/- 0.05 (4%patient/yr); treatment failure: 78.81% +/- 0.05 (1.12% patient/yr), 76.44%+/- 0.09 (0.62% patient/yr), 80.97% +/- 0.04 (1% patient/yr); allvalve-related morbidity and mortality: 40.43% +/- 0.13 (1.93% patient/yr),57.76% +/- 0.08 (1.43% patient/yr), 14.96% +/- 0.05 (4.18% patient/yr); allvalve- related morbidity and mortality at 5 years: 91.97% +/- 0.02 (7.8%patient/yr), 87.06% +/- 0.03 (3.6% patient/yr), 90.27% +/- 0.03 (2.6%patient/yr); at 10 years: 80.4% +/- 0.03 (4.6% patient/yr), 75.91% +/- 0.03(2.6% patient/yr), 37.44% +/- 0.05 (4.18% patient/yr).(ABSTRACT TRUNCATEDAT 250 WORDS) © Springer-Verlag 1995 European Journal of Cardio-Thoracic Surgery Elsevier Science B.V. 9/4(1995-04), 181-189 1010-7940 9:4<181 1995 9 ejcts https://doi.org/10.1016/S1010-7940(05)80142-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1016/S1010-7940(05)80142-3 text/html Onlinezugriff via DOI NATIONALLICENCE 773 0- European Journal of Cardio-Thoracic Surgery Elsevier Science B.V 9/4(1995-04), 181-189 1010-7940 9:4<181 1995 9 ejcts Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford